CRSP
CRISPR Therapeutics AG
+5.37 (+10.28%)57.58USD1.4M成交股數5.6B市值–本益比(近四季)415.7股價營收比+1041.4%營收年增(近四季)2026-11-09下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 10.2M+1077% | 1.5M-96% | 889K+48% | 892K+73% | 865K+72% | 35.7M | 602K-99% | 517K-99% | 504K | 0 | 70.0M | 100M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 67.2M | 68.6M | 58.9M | 69.9M | 72.5M | 71.7M | 82.2M | 80.2M | 76.2M | 90.7M | 102M | 99.9M |
| 銷售管理費用 | 17.6M | 17.2M | 16.9M | 18.9M | 19.3M | 18.1M | 17.4M | 19.5M | 18.0M | 18.3M | 19.0M | 22.4M |
| 營業利益 | −117M-21% | −130M+102% | −132M+20% | −229M+52% | −148M+6% | −64.6M-51% | −110M+16% | −151M+135% | −141M | −132M | −95.2M | −64.5M |
| 營業利益率 | -1,151.8% | -8,933.3% | -14,854.8% | -25,709.0% | -17,158.8% | -181.0% | -18,294.0% | -29,257.3% | -27,894.2% | – | -136.0% | -64.5% |
| 稅後淨利 | −91.2M-33% | −123M+229% | −106M+24% | −209M+65% | −136M+17% | −37.3M-67% | −85.9M+11% | −126M+138% | −117M | −112M | −77.7M | −53.1M |
| 淨利率 | -895.3% | -8,431.5% | -11,973.1% | -23,379.9% | -15,722.1% | -104.5% | -14,276.1% | -24,450.3% | -23,133.1% | – | -111.1% | -53.1% |
| 稀釋 EPS | -0.94-41% | -1.28+212% | -1.17+16% | -2.40+61% | -1.58+10% | -0.41-71% | -1.01+3% | -1.49+122% | -1.43 | -1.41 | -0.98 | -0.67 |
| 稀釋股數 | 96.5M | 96.1M | 91.3M | 87.1M | 85.9M | 84.4M | 85.2M | 84.9M | 81.8M | 79.4M | 79.1M | 78.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 291M | 423M | 286M | 194M | 235M | 298M | 226M | 484M | 707M | 528M | 445M | 344M |
| 應收帳款 | – | – | 0 | 0 | 0 | 25.0M | 0 | 0 | 0 | – | 70.0M | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 2.7B | 2.7B | 2.2B | 2.0B | 2.2B | 2.2B | 2.3B | 2.3B | 2.4B | 2.1B | 2.2B | 2.2B |
| 有息負債 | 586M | 585M | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 904M | 911M | 329M | 319M | 337M | 310M | 316M | 359M | 355M | 359M | 381M | 389M |
| 股東權益 | 1.7B | 1.8B | 1.9B | 1.7B | 1.8B | 1.9B | 1.9B | 2.0B | 2.1B | 1.7B | 1.8B | 1.9B |
| 負債比 | 34.1% | 33.4% | 14.7% | 15.7% | 15.6% | 13.8% | 14.0% | 15.3% | 14.6% | 17.2% | 17.3% | 17.4% |
| 淨現金(現金 − 有息負債) | −295M | −162M | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −109M | – | – | −53.9M-149% | – | – | – | 110M | – | – | 8.8M |
| 資本支出 | – | 504K | – | – | 206K | – | – | – | 721K | – | – | 3.1M |
| 自由現金流 | – | −109M | – | – | −54.2M-150% | – | – | – | 109M | – | – | 5.7M |
| 折舊攤銷 | – | 4.3M | – | – | 4.7M | – | – | – | 4.8M | – | – | 5.1M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -7,503.5% | – | – | -6,260.5% | – | – | – | 21,633.1% | – | – | 5.7% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 3.5M
| Grant | 3.5M | 100.0% | +51.7% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 3.5M | -90.6% | −582M | -16,569.8% | -6.47 | −346M |
| FY2024 | 37.3M | -89.9% | −366M | -981.5% | -4.34 | −145M |
| FY2023 | 371M | +30885.5% | −154M | -41.4% | -1.94 | −270M |
| FY2022 | 1.2M | -99.9% | −650M | -54,271.7% | -8.36 | −533M |
| FY2021 | 915M | +127154.9% | 378M | 41.3% | 4.70 | 457M |
| FY2020 | 719K | -99.8% | −349M | -48,520.9% | -5.29 | −257M |
| FY2019 | 290M | +9169.8% | 66.9M | 23.1% | 1.17 | 50.0M |
| FY2018 | 3.1M | – | −165M | -5,281.1% | -3.44 | −99.0M |